Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02520557
Other study ID # SEP093-452
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date November 30, 2015
Est. completion date January 21, 2020

Study information

Verified date January 2021
Source Sunovion
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The reason for this study is to understand if people with certain genes are predisposed to develop severe skin reactions after they are administered Eslicarbazepine Acetate. Currently there is no information that suggests that certain individuals who use Eslicarbazepine Acetate are predisposed to develop severe skin reactions. However, previous research has shown that seizure medicines like carbamazepine (Tegretol®) and oxcarbazepine (Trileptal®, Oxtellar XR®) are more likely to cause severe drug related skin reactions in some people of Asian ancestry who have specific genes. These are genes found in an area of chromosomes called the Major Histocompatibility Complex. This association is called a genetic risk factor. The study objective is to compare information that is obtained from individuals with a history of seizure disorders who develop severe skin reactions while using Eslicarbazepine Acetate to a group of patients who also have a history of seizure disorders and do not have a history of a severe skin reaction after using Eslicarbazepine Acetate.


Description:

This study is a genetic case-control study conducted in the United States. In case-control studies, cases with a condition of interest (in this case, individuals with SCAR [severe cutaneous adverse reactions] after initiating ESL); and controls, individuals known to not have the condition of interest (in this case ESL users without SCAR), are identified. Cases will be individuals with documented definite or probable Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS) or symptom onset consistent with one of these conditions within the first 4 months of using ESL (including up to 14 days after discontinuing ESL), ascertained through PPD Pharmacovigilance (PVG) (Sponsor CRO). Controls will be individuals who have used ESL for at least 6 weeks but did not develop any SCAR and will be matched by genetic ancestry classification in a ratio of up to 10 controls per case. Controls will be collected prospectively, so that a pool of ESL-tolerant patients will be identified independently of the collection of cases. Controls will be selected from among: - Ongoing subjects in clinical studies of ESL; and - Patients prescribed ESL who may be asked to participate by neurologists at high-prescribing practices with high ethnic diversity. Blood or saliva samples for genotyping ancestry markers (for matching controls to cases) and sequencing the HLA regions will be collected from cases and control subjects after they have provided consent for participation in a genetic study. In addition, a blood sample will be requested from subjects to assess the relationship with specific viral markers.


Recruitment information / eligibility

Status Terminated
Enrollment 121
Est. completion date January 21, 2020
Est. primary completion date January 21, 2020
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Study subjects must have the ability to comprehend the informed consent and be willing to provide informed consent and consent for storage and DNA testing of blood or saliva. For subjects who are unable to comprehend the written consent, a legal guardian who is able to describe and provide an understanding of the informed consent to the subject must sign all study consent forms on behalf of the subject. - The study subject or parent/guardian must possess an educational level and degree of understanding of English or Spanish that enables them to communicate suitably with the local investigator and study coordination staff. Specific criteria for cases and controls: - Cases will be individuals with documented definite or probable Stevens-Johnson syndrome (SJS) - Toxic epidermal necrolysis (TEN), acute generalized exanthematous pustulosis (AGEP), or drug reaction with eosinophilia and systemic symptoms (DRESS) - Symptom onset consistent with one of these conditions within the first 4 months of using ESL (including up to 14 days after discontinuing ESL). - Controls will be individuals who have used ESL for at least 6 weeks and who have not developed SCAR. Exclusion Criteria:

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Blood or Saliva
To screen for HLA genotypes that may place patients at high risk of SCAR when they use ESL.

Locations

Country Name City State
United States University of Pennsylvania Perlman School of Medicine Philadelphia Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Sunovion University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Severe Cutaneous Adverse Reactions (SCAR) while using ESL up to 4 months
Secondary HLA genotypes that may place patients at high risk of SCAR when they use ESL. up to 4 months
See also
  Status Clinical Trial Phase
Recruiting NCT03646955 - Partial Breast Versus no Irradiation for Women With Early Breast Cancer N/A
Completed NCT01706848 - Celotres for Improvement in Wound Healing and Resulting Scar Consequences Following Suturing of a Wound N/A
Recruiting NCT01177358 - Botox in the Healing of Surgical Wounds of the Neck Phase 2
Terminated NCT01459666 - Forehead Scars Following Mohs Micrographic Surgery and Reconstruction for Skin Cancer Phase 4
Completed NCT00970671 - Treatment of Surgical Scars Using the Pulsed Dye Laser N/A
Recruiting NCT03561376 - Zinc Oxide Versus Petrolatum Following Skin Surgery Early Phase 1
Completed NCT05293652 - Effect of Hydrocortisone Iontophoresis Versus Hydrocortisone Phonophoresis On Post Surgical Scar N/A
Recruiting NCT03406143 - Evaluation of the Effect of CGF in Promoting Mechanical-stretch Induced in Vivo Skin Regeneration N/A
Completed NCT05527756 - Evaluation of the Cosmetic Outcomes of Totally Endoscopic Cardiac Surgery
Completed NCT02886988 - Early Postoperative Prevention and Treatment of Median Sternotomy Scars With Botulinum Toxin Type A Injection Phase 2/Phase 3
Completed NCT05618912 - Scar Appearance After Postoperative Hydrocolloid Dressing Versus Standard Petrolatum Ointment N/A
Recruiting NCT05408117 - Impact of Suture Type on Pigment Disturbances in Patients of Skin of Color N/A
Completed NCT04169438 - Pilot Study Investigating a Restorative Wound Care Cream Together With Petrolatum on Surgical Excisions N/A
Not yet recruiting NCT04621994 - Cesarean Wound Closure: Dermabond Versus Steri Strips N/A
Withdrawn NCT03395678 - Acne Scarring in Skin of Color: Laser vs Microneedling N/A
Completed NCT02744950 - Comparison of Scar Results and Time for Closures of Scalp Defects Via Pulley Sutures or Layered Repairs N/A
Not yet recruiting NCT01005992 - Fractional Photothermolysis for the Treatment of Burn Scars Phase 1
Completed NCT04870008 - Aesthetic Outcome of Running Cuticular Suture Distance (2mm vs 5mm) N/A
Recruiting NCT04506255 - Silicone Taping for the Improvement of Abdominal Donor Site Scars N/A
Recruiting NCT06386549 - Effect of a Tele-rehabilitation Programme in Children With Burns: a Randomized Controlled Trial N/A